BRAF and melanoma: compared intermittent dosing of dabrafenib and trametinib (3 weeks off/5 weeks on) versus the standard continuous treatment in patients with metastatic BRAF-mutated melanoma, in order to verify the role of drug “holiday” in overcoming acquired resistance and improving the outcome (44).